Mariner’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$58.8M Buy
131,600
+3,135
+2% +$1.46M 0.07% 237
2025
Q4
$58.2M Buy
128,465
+18,214
+17% +$7.85M 0.07% 230
2025
Q3
$43.2M Sell
110,251
-8,872
-7% -$3.71M 0.06% 269
2025
Q2
$53M Buy
119,123
+2,562
+2% +$1.18M 0.08% 226
2025
Q1
$56.5M Sell
116,561
-5,856
-5% -$2.73M 0.09% 194
2024
Q4
$49.3M Sell
122,417
-1,077
-0.9% -$499K 0.08% 213
2024
Q3
$57.4M Buy
123,494
+2,082
+2% +$1M 0.1% 188
2024
Q2
$56.9M Buy
121,412
+5,951
+5% +$2.58M 0.11% 170
2024
Q1
$48.3M Buy
115,461
+6,518
+6% +$2.76M 0.1% 197
2023
Q4
$44.3M Buy
108,943
+12,331
+13% +$4.56M 0.11% 189
2023
Q3
$33.6M Buy
96,612
+3,382
+4% +$1.18M 0.09% 205
2023
Q2
$32.8M Buy
93,230
+1,828
+2% +$616K 0.09% 211
2023
Q1
$28.8M Buy
91,402
+59,637
+188% +$17.9M 0.08% 223
2022
Q4
$9.2M Buy
31,765
+13,022
+69% +$3.97M 0.03% 429
2022
Q3
$5.43M Buy
18,743
+7,262
+63% +$2.09M 0.02% 488
2022
Q2
$3.23M Buy
11,481
+460
+4% +$123K 0.01% 589
2022
Q1
$2.88M Buy
+11,021
New +$2.62M 0.01% 630
2019
Q3
Sell
-1,302
Closed -$239K 1050
2019
Q2
$239K Buy
1,302
+39
+3% +$6.82K ﹤0.01% 975
2019
Q1
$232K Buy
+1,263
New +$233K ﹤0.01% 915

Other funds holding VRTX

Mariner's VRTX Position: Q1 2026 in Review

Mariner increased its Vertex Pharmaceuticals (VRTX) stake by 2.4% in Q1 2026, buying an estimated $1.46M and bringing the position to 131,600 shares worth $58.8M. The position accounts for 0.07% of the portfolio, ranked #237.

Mariner first reported a position in VRTX in Q1 2019 and has held it in 19 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Mariner held 131,600 shares of Vertex Pharmaceuticals worth $58.8M as of Q1 2026.
  • Mariner bought 3,135 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.46M.
  • Vertex Pharmaceuticals made up 0.07% of Mariner's portfolio in Q1 2026, its #237 holding.
  • Mariner first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 19 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.